Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 30 PAGES: 143

More Info
									Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review,
                        H1 2012


                                                                                          Reference Code: GMDHC1822IDB
                                                                                             Publication Date: March 2012




Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                             GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 9
Introduction....................................................................................................................................................................................... 10
    Global Markets Direct Report Coverage ...................................................................................................................................... 10
Keratoconjunctivitis sicca (Dry Eye) Overview ................................................................................................................................. 11
Therapeutics Development............................................................................................................................................................... 12
    An Overview of Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) ................................................................................. 12
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Development by Companies .................................................................... 14
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Investigation by Universities/Institutes ..................................................... 18
Late Stage Products ......................................................................................................................................................................... 19
    Comparative Analysis .................................................................................................................................................................. 19
Mid Clinical Stage Products.............................................................................................................................................................. 20
    Comparative Analysis .................................................................................................................................................................. 20
Early Clinical Stage Products ........................................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 22
    Comparative Analysis .................................................................................................................................................................. 22
Keratoconjunctivitis sicca (Dry Eye) Therapeutics – Products under Development by Companies.................................................. 23
Keratoconjunctivitis sicca (Dry Eye) Therapeutics – Products under Investigation by Universities/Institutes ................................... 26
Companies Involved in Keratoconjunctivitis sicca (Dry Eye) Therapeutics Development ................................................................ 27
    Alcon, Inc. .................................................................................................................................................................................... 27
    Allergan, Inc................................................................................................................................................................................. 28
    Bayer HealthCare AG .................................................................................................................................................................. 29
    Merck & Co., Inc. ......................................................................................................................................................................... 30
    Santen Pharmaceutical Co., Ltd. ................................................................................................................................................. 31
    arGentis Pharmaceuticals, LLC ................................................................................................................................................... 32
    Sylentis ........................................................................................................................................................................................ 33
    Novagali Pharma SA ................................................................................................................................................................... 34
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 35
    Kissei Pharmaceutical Co., Ltd. ................................................................................................................................................... 36
    Pfizer Inc...................................................................................................................................................................................... 37
    ISTA Pharmaceuticals, Inc. ......................................................................................................................................................... 38
    InSite Vision Incorporated ........................................................................................................................................................... 39
    iCo Therapeutics Inc.................................................................................................................................................................... 40
    Can-Fite BioPharma Ltd. ............................................................................................................................................................. 41
    NovaBay Pharmaceuticals, Inc. ................................................................................................................................................... 42
    RegeneRx Biopharmaceuticals, Inc............................................................................................................................................. 43
    Sirion Therapeutics, Inc. .............................................................................................................................................................. 44
    R-Tech Ueno, Ltd. ....................................................................................................................................................................... 45
    SCYNEXIS, Inc............................................................................................................................................................................ 46
    Parion Sciences, Inc. ................................................................................................................................................................... 47



Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                                  GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    SARcode Corporation.................................................................................................................................................................. 48
    Resolvyx Pharmaceuticals, Inc .................................................................................................................................................... 49
    Morria Biopharmaceuticals Plc .................................................................................................................................................... 50
    SIFI Pharma ................................................................................................................................................................................ 51
    DSM Nutritional Products AG ...................................................................................................................................................... 52
    Altacor Ltd. .................................................................................................................................................................................. 53
    Mimetogen Pharmaceuticals Inc.................................................................................................................................................. 54
Keratoconjunctivitis sicca (Dry Eye) – Therapeutics Assessment .................................................................................................... 55
    Assessment by Monotherapy Products ....................................................................................................................................... 55
    Assessment by Route of Administration ...................................................................................................................................... 56
    Assessment by Molecule Type .................................................................................................................................................... 58
Drug Profiles..................................................................................................................................................................................... 60
    Prolacria - Drug Profile ................................................................................................................................................................ 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    Prolacria - Drug Profile ................................................................................................................................................................ 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Tofacitinib - Drug Profile .............................................................................................................................................................. 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Ecabet - Drug Profile ................................................................................................................................................................... 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    AIN457 - Drug Profile .................................................................................................................................................................. 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    ARG103 - Drug Profile ................................................................................................................................................................. 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Xerophthalmia Program - Drug Profile ........................................................................................................................................ 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action ............................................................................................................................................................... 70
        R&D Progress ......................................................................................................................................................................... 70
    ARG101 - Drug Profile ................................................................................................................................................................. 71
        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71


Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                                GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    ARG102 - Drug Profile ................................................................................................................................................................. 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    CF101 - Drug Profile.................................................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    RGN-259 - Drug Profile ............................................................................................................................................................... 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    OPC-12759E - Drug Profile ......................................................................................................................................................... 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    Cyclosporine - Drug Profile .......................................................................................................................................................... 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ......................................................................................................................................................................... 79
    Remura - Drug Profile .................................................................................................................................................................. 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    SAR1118 - Drug Profile ............................................................................................................................................................... 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    AL 43546 - Drug Profile ............................................................................................................................................................... 83
        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83
    Cyclokat - Drug Profile ................................................................................................................................................................. 84
        Product Description................................................................................................................................................................. 84
        Mechanism of Action ............................................................................................................................................................... 84
        R&D Progress ......................................................................................................................................................................... 84
    RX-10001 - Drug Profile .............................................................................................................................................................. 86
        Product Description................................................................................................................................................................. 86
        Mechanism of Action ............................................................................................................................................................... 86
        R&D Progress ......................................................................................................................................................................... 86
    ProtoCure - Drug Profile .............................................................................................................................................................. 88
        Product Description................................................................................................................................................................. 88
        Mechanism of Action ............................................................................................................................................................... 88
        R&D Progress ......................................................................................................................................................................... 88


Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                             GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    iCo-008 - Drug Profile .................................................................................................................................................................. 89
        Product Description................................................................................................................................................................. 89
        Mechanism of Action ............................................................................................................................................................... 89
        R&D Progress ......................................................................................................................................................................... 89
    Mapracorat - Drug Profile ............................................................................................................................................................ 91
        Product Description................................................................................................................................................................. 91
        Mechanism of Action ............................................................................................................................................................... 91
        R&D Progress ......................................................................................................................................................................... 91
    RX-20001 - Drug Profile .............................................................................................................................................................. 93
        Product Description................................................................................................................................................................. 93
        Mechanism of Action ............................................................................................................................................................... 93
        R&D Progress ......................................................................................................................................................................... 93
    RU-101 - Drug Profile .................................................................................................................................................................. 94
        Product Descriptio
								
To top